BR9908082A - Class II major histocompatibility complex fusion protein, conjugated from the multimeric major histocompatibility complex binding domains, processes for detecting t cells having a specificity of the defined mhc / peptide complex, to give an individual adoptive immunity to a defined complex mhc / peptide, to stimulate or activate t cells reactive to a defined mhc / peptide complex, to selectively kill t cells reactive to a defined mhc / peptide complex, to tolerate a human individual to a defined mhc / peptide complex , and isolated nucleic acid - Google Patents

Class II major histocompatibility complex fusion protein, conjugated from the multimeric major histocompatibility complex binding domains, processes for detecting t cells having a specificity of the defined mhc / peptide complex, to give an individual adoptive immunity to a defined complex mhc / peptide, to stimulate or activate t cells reactive to a defined mhc / peptide complex, to selectively kill t cells reactive to a defined mhc / peptide complex, to tolerate a human individual to a defined mhc / peptide complex , and isolated nucleic acid

Info

Publication number
BR9908082A
BR9908082A BR9908082-6A BR9908082A BR9908082A BR 9908082 A BR9908082 A BR 9908082A BR 9908082 A BR9908082 A BR 9908082A BR 9908082 A BR9908082 A BR 9908082A
Authority
BR
Brazil
Prior art keywords
complex
peptide
mhc
cells
peptide complex
Prior art date
Application number
BR9908082-6A
Other languages
Portuguese (pt)
Inventor
Kai W Wucherpfennig
Jack L Strominger
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of BR9908082A publication Critical patent/BR9908082A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"PROTEìNA DE FUSãO DO COMPLEXO DE HISTOCOMPATIBILIDADE PRINCIPAL CLASSE II, CONJUGADO DOS DOMìNIOS DE LIGAçãO DO COMPLEXO DE HISTOCOMPATIBILIDADE PRINCIPAL MULTIMéRICO, PROCESSOS PARA DETECTAR CéLULAS T TENDO UMA ESPECIFICIDADE DO COMPLEXO DEFINIDO DE MHC/PEPTìDEO, PARA CONFERIR A UM INDIVìDUO IMUNIDADE ADOTIVA A UM COMPLEXO DEFINIDO DE MHC/PEPTìDEO, PARA ESTIMULAR OU ATIVAR AS CéLULAS T REATIVAS A UM COMPLEXO DEFINIDO DE MHC/PEPTìDEO, PARA SELETIVAMENTE MATAR CéLULAS T REATIVAS A UM COMPLEXO DEFINIDO DE MHC/PEPTìDEO, PARA TOLERIZAR UM INDIVìDUO HUMANO A UM COMPLEXO DEFINIDO DE MHC/PEPTìDEO, E, áCIDO NUCLEICO ISOLADO" A presente invenção é direcionada ao campo da imunologia. Em particular, a presente invenção é direcionada ao planejamento, produção e uso de proteínas e conjugados de fusão do domínio de ligação do Complexo de Histocompatibilidade Principal monovalente, multivalente e multimérico."CLASS II MAIN HISTOCOMPATIBILITY COMPLEX FUSION PROTEIN, CONJUGATE OF THE MULTIMERICAL MAIN HISTOCOMPATIBILITY CONNECTING DOMAINS, PROCESSES TO DETECT CELLS HAVING A UNIT SPECIFICITY OF THE COMPLEX, DEFINED MHC / PEPTIDE, TO STIMULATE OR ACTIVATE TACTORY CELLS TO A DEFINED MHC / PEPTIDE COMPLEX, TO SELECTIVELY KILL REACTIVE T CELLS TO A DEFINED MHC / PEPTIDE COMPLEX, TO DETERMINE A HYDROID DETERMINATE A HUMAN DETERMINATION PEPTIDE, AND, ISOLATED NUCLEIC ACID "The present invention is directed to the field of immunology. In particular, the present invention is directed to the planning, production and use of proteins and fusion conjugates of the monovalent, multivalent and multimeric Principal Histocompatibility Complex.

BR9908082-6A 1998-02-19 1999-02-19 Class II major histocompatibility complex fusion protein, conjugated from the multimeric major histocompatibility complex binding domains, processes for detecting t cells having a specificity of the defined mhc / peptide complex, to give an individual adoptive immunity to a defined complex mhc / peptide, to stimulate or activate t cells reactive to a defined mhc / peptide complex, to selectively kill t cells reactive to a defined mhc / peptide complex, to tolerate a human individual to a defined mhc / peptide complex , and isolated nucleic acid BR9908082A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7535198P 1998-02-19 1998-02-19
PCT/US1999/003603 WO1999042597A1 (en) 1998-02-19 1999-02-19 Monovalent, multivalent, and multimeric mhc binding domain fusion proteins and conjugates, and uses therefor

Publications (1)

Publication Number Publication Date
BR9908082A true BR9908082A (en) 2000-10-31

Family

ID=22125136

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9908082-6A BR9908082A (en) 1998-02-19 1999-02-19 Class II major histocompatibility complex fusion protein, conjugated from the multimeric major histocompatibility complex binding domains, processes for detecting t cells having a specificity of the defined mhc / peptide complex, to give an individual adoptive immunity to a defined complex mhc / peptide, to stimulate or activate t cells reactive to a defined mhc / peptide complex, to selectively kill t cells reactive to a defined mhc / peptide complex, to tolerate a human individual to a defined mhc / peptide complex , and isolated nucleic acid

Country Status (8)

Country Link
EP (1) EP1054984A1 (en)
JP (1) JP2002504342A (en)
AU (1) AU765378B2 (en)
BR (1) BR9908082A (en)
CA (1) CA2321262A1 (en)
IL (1) IL137706A0 (en)
NZ (1) NZ506071A (en)
WO (1) WO1999042597A1 (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ331688A (en) 1996-03-28 2000-02-28 Univ Johns Hopkins Soluble divalent and multivalent heterodimeric analogs of proteins
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
DE19963859A1 (en) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- or oligomer of a di-, tri-, quattro- or pentamer of recombinant fusion proteins
EP1377609B1 (en) * 2001-03-14 2015-06-24 Dako Denmark A/S Mhc molecule constructs and their uses for diagnosis and therapy
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
EP1430084A2 (en) * 2001-09-17 2004-06-23 GenPat77 Pharmacogenetics AG Peptides capable of modulating immune response
US7175983B2 (en) 2001-11-02 2007-02-13 Abmaxis, Inc. Adapter-directed display systems
CN1615316A (en) * 2001-11-16 2005-05-11 法麦克萨有限公司 Novel immunogenic mimetics of multimer proteins
GB2392158B (en) * 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
EP1400534B1 (en) * 2002-09-10 2015-10-28 Affimed GmbH Human CD3-specific antibody with immunosuppressive properties
EP2204190A1 (en) * 2003-07-15 2010-07-07 Chugai Seiyaku Kabushiki Kaisha IgM production by transformed cells and methods for quantifying said IgM production
JP5097400B2 (en) * 2003-09-03 2012-12-12 デンドリセラピューティクス、インク． Combined vaccine
GB2408507B (en) * 2003-10-06 2005-12-14 Proimmune Ltd Chimeric MHC protein and oligomer thereof for specific targeting
JP4762717B2 (en) 2003-10-09 2011-08-31 中外製薬株式会社 IgM high concentration stabilization solution
GB2409456B (en) * 2003-10-30 2006-01-04 Proimmune Ltd Oligomeric receptor ligand pair member complexes
CA2595462A1 (en) * 2005-01-21 2006-07-27 Nalan Utku Hla fusion molecules and uses thereof
US20140105980A1 (en) * 2012-10-11 2014-04-17 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP3023436A1 (en) 2007-07-03 2016-05-25 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
EP2197908A2 (en) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
KR20140114859A (en) * 2012-01-06 2014-09-29 오레곤 헬스 앤드 사이언스 유니버시티 Partial mhc constructs and methods of use
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US10752949B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9951386B2 (en) 2014-06-26 2018-04-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
CA2881685C (en) 2012-08-14 2023-12-05 10X Genomics, Inc. Microcapsule compositions and methods
US10584381B2 (en) 2012-08-14 2020-03-10 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11591637B2 (en) 2012-08-14 2023-02-28 10X Genomics, Inc. Compositions and methods for sample processing
US10323279B2 (en) 2012-08-14 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9701998B2 (en) 2012-12-14 2017-07-11 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10273541B2 (en) 2012-08-14 2019-04-30 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9567631B2 (en) 2012-12-14 2017-02-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
CA2886120A1 (en) 2012-10-08 2014-04-17 St. Jude Children's Research Hospital Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
US10533221B2 (en) 2012-12-14 2020-01-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
CA2900543C (en) 2013-02-08 2023-01-31 10X Genomics, Inc. Partitioning and processing of analytes and other species
RU2696876C2 (en) 2013-11-04 2019-08-07 Ютиай Лимитед Партнершип Methods and compositions for stable immunotherapy
CN106413896B (en) 2014-04-10 2019-07-05 10X基因组学有限公司 For encapsulating and dividing fluid means, system and method and its application of reagent
BR112016027912A2 (en) 2014-05-29 2018-02-20 Macrogenics, Inc. trypecific binding molecule capable of immunospecific binding to three different epitopes, pharmaceutical composition, cancer treatment method, method of treating a disease associated with the presence of a pathogen, anti-ror1 antibody, or ror1 binding fragment, bispecific antibody fragment, bite or single chain antibody, and cancer treatment method
US11585806B2 (en) 2014-06-13 2023-02-21 Immudex Aps General detection and isolation of specific cells by binding of labeled molecules
JP6838969B2 (en) 2014-06-26 2021-03-03 １０エックス ジェノミクス， インコーポレイテッド Method for Analyzing Nucleic Acids Derived from Individual Cells or Cell Populations
CN112126675B (en) 2015-01-12 2022-09-09 10X基因组学有限公司 Method and system for preparing nucleic acid sequencing library and library prepared by using same
EP4286516A3 (en) 2015-02-24 2024-03-06 10X Genomics, Inc. Partition processing methods and systems
US20190060484A1 (en) 2015-05-06 2019-02-28 Uti Limited Partnership Nanoparticle compositions for sustained therapy
CN108136010A (en) 2015-10-08 2018-06-08 宏观基因有限公司 For the conjoint therapy for the treatment of cancer
MA45489A (en) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh CELL CULTURE PROCESSES, ASSOCIATED KITS AND APPARATUS
SG11201804086VA (en) 2015-12-04 2018-06-28 10X Genomics Inc Methods and compositions for nucleic acid analysis
US10815525B2 (en) 2016-12-22 2020-10-27 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10550429B2 (en) 2016-12-22 2020-02-04 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10011872B1 (en) 2016-12-22 2018-07-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
WO2018140966A1 (en) 2017-01-30 2018-08-02 10X Genomics, Inc. Methods and systems for droplet-based single cell barcoding
CA3060526A1 (en) 2017-04-27 2018-11-01 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
US10844372B2 (en) 2017-05-26 2020-11-24 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
EP4230746A3 (en) 2017-05-26 2023-11-01 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
SG11201913654QA (en) 2017-11-15 2020-01-30 10X Genomics Inc Functionalized gel beads
US10829815B2 (en) 2017-11-17 2020-11-10 10X Genomics, Inc. Methods and systems for associating physical and genetic properties of biological particles
EP3752832A1 (en) 2018-02-12 2020-12-23 10X Genomics, Inc. Methods characterizing multiple analytes from individual cells or cell populations
CN112262218A (en) 2018-04-06 2021-01-22 10X基因组学有限公司 System and method for quality control in single cell processing
WO2020018715A1 (en) * 2018-07-17 2020-01-23 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
WO2020127222A2 (en) 2018-12-17 2020-06-25 Immudex Aps Panel comprising borrelia mhc multimers
WO2022109339A1 (en) 2020-11-20 2022-05-27 Becton, Dickinson And Company Use of dextramer in single cell analysis
CA3215077A1 (en) * 2021-04-07 2022-10-13 Thomas J. Malia Peptide-mhc-immunoglobulin multimers and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ331688A (en) * 1996-03-28 2000-02-28 Univ Johns Hopkins Soluble divalent and multivalent heterodimeric analogs of proteins
US6211342B1 (en) * 1996-07-18 2001-04-03 Children's Hospital Medical Center Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
DE69730038T2 (en) * 1996-08-16 2004-11-25 The President And Fellows Of Harvard College, Cambridge SOLUBLE MONOVALENTS AND MULTIVALENTS MHC CLASS II FUSION PROTEINS AND THEIR USE
AU5428598A (en) * 1997-08-19 1999-03-08 Mount Sinai School Of Medicine Of The City University Of New York, The Epitope-bearing major histocompatibility complex class II element/immunoglobulin chimeric molecules

Also Published As

Publication number Publication date
IL137706A0 (en) 2001-10-31
CA2321262A1 (en) 1999-08-26
WO1999042597A9 (en) 1999-11-04
AU765378B2 (en) 2003-09-18
JP2002504342A (en) 2002-02-12
AU2774899A (en) 1999-09-06
EP1054984A1 (en) 2000-11-29
WO1999042597A1 (en) 1999-08-26
NZ506071A (en) 2003-05-30

Similar Documents

Publication Publication Date Title
BR9908082A (en) Class II major histocompatibility complex fusion protein, conjugated from the multimeric major histocompatibility complex binding domains, processes for detecting t cells having a specificity of the defined mhc / peptide complex, to give an individual adoptive immunity to a defined complex mhc / peptide, to stimulate or activate t cells reactive to a defined mhc / peptide complex, to selectively kill t cells reactive to a defined mhc / peptide complex, to tolerate a human individual to a defined mhc / peptide complex , and isolated nucleic acid
Bocchia et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides
NZ333915A (en) Soluble monovalent and multivalent MHC class II fusion proteins
DE69837845D1 (en) OSTEOPROTEGER BINDING PROTEINS AND RECEPTORS
DE69326064T2 (en) Human protein P53 peptides for use in human cytotoxic T cell response inducing compositions and human P53 protein specific T lymphocytes
ATE397457T1 (en) STIMULATION OF T-CELLS AGAINST SELF-ANTIGENS USING CTLA-4 INHIBITING AGENTS
DK0506884T3 (en) Method of delivering molecules to eukaryotic cells
FR12C0004I2 (en) ANTIBODIES TO HUMAN CTLA-4 ANTIGEN AND USE
PT1066380E (en) T SOLUVEL CELL RECEIVER
DE60039752D1 (en) PREPARATION OF TETRAVALENT ANTIBODY
ATE196314T1 (en) METHODS AND COMPOSITIONS FOR PREVENTING INFLAMMATION AND ANGIOGENESIS IN MAMMALS CONTAINING CD97 ALPHA SUBUNIT
Chess et al. Leukocyte inhibitory factor (LIF): production by purified human T and B lymphocytes
KR960705848A (en) NOVEL PEPTIDES DERIVED FROM AUTOANTIGEN FOR USE IN IMMUNOTHERAPHY OF AUTOIMMUNE DISEASE Derived from Autoantigens for Use in Immune Treatment of Autoimmune Diseases
NO991926D0 (en) Soluble lymphotoxin <beta> receptors, anti-lymphotoxin receptor antibody and anti-lymphotoxin ligand antibody as therapeutic agents for the treatment of immunological diseases
AU9363398A (en) Hepatitis c receptor protein cd81
ATE273390T1 (en) MAMMAL EDG-7 RECEPTOR HOMOLOGUE
WO2001042287A3 (en) Putative human g-protein coupled receptors
DE69631624D1 (en) ANTIBODIES AGAINST HUMAN RESTRICTIN
BR0113623A (en) Synthetic erythropoiesis stimulating proteins
ATE407944T1 (en) PROTEIN MTR1 RELATED TO TRP PROTEINS AND DNA CODING SEQUENCE THEREOF
BR9913991A (en) Subregulation methods of the immune response to therapeutic proteins
Iwata et al. Association of glycosylation-inhibiting factor with plasma membranes of T suppressor cell hybridomas.
傅国辉 et al. Study of C-terminal Properties of Human Erythrocyte Membrane Protein Band 3
ATE282704T1 (en) ISOLATED AND PURIFIED HUMAN SOLUBLE GUANYLYL CYCLASE ALPHA1/BETA1 (HSGC ALPHA1/BETA1)
ES2136534A1 (en) Use of [omega]-1 secalin for the detection and monitoring of coeliac disease

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US)

Free format text: A FIM DE ATENDER O SOLICITADO NA PETICAO DE TRANSFERENCIA NO 020060013684/RJ DE 31/01/06, QUEIRA APRESENTAR O DOCUMENTO DE CESSAO ASSINADO PELA CEDENTE, BEM COMO A RESPECTIVA NOTARIZACAO E LEGALIZACAO CONSULAR.

B25A Requested transfer of rights approved

Owner name: PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) , DA

Free format text: TRANSFERIDO PARTE DOS DIREITOS DE: PRESIDENT AND FELLOWS OF HARVARD COLLEGE

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A E 10A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 1994 DE 24/03/2009

B15K Others concerning applications: alteration of classification

Ipc: C07K 17/02 (2006.01), A61K 35/17 (2015.0